title: Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist.
abstract: OBJECTIVE
  To determine whether inhaled salmeterol, a new long acting inhaled beta adrenergic agonist, reduces nocturnal bronchoconstriction and improves sleep quality in patients with nocturnal asthma.
  
  
  METHODS
  Randomised, double blind, placebo controlled crossover study.
  
  
  METHODS
  Hospital outpatient clinics in Edinburgh.
  
  
  METHODS
  Twenty clinically stable patients (13 women, seven men) with nocturnal asthma, median age 39 (range 18-60) years.
  
  
  METHODS
  Salmeterol 50 micrograms and 100 micrograms and placebo taken each morning and evening by metered dose inhaler. Rescue salbutamol inhalers were provided throughout the run in and study periods.
  
  
  METHODS
  Improvement in nocturnal asthma as measured by peak expiratory flow rates and change in sleep quality as measured by electroencephalography.
  
  
  RESULTS
  Salmeterol improved the lowest overnight peak flow rate at both 50 micrograms (difference in median values (95% confidence interval for difference in medians) 69 (18 to 88) l/min) and 100 micrograms (72 (23 to 61) l/min) doses twice daily. While taking salmeterol 50 micrograms twice daily patients had an objective improvement in sleep quality, spending less time awake or in light sleep (-9 (-4 to -44) min) and more time in stage 4 sleep (26 (6-34) min).
  
  
  CONCLUSIONS
  Salmeterol is an effective long acting inhaled bronchodilator for patients with nocturnal asthma and at a dose of 50 micrograms twice daily improves objective sleep quality.
authors.affiliation: University Respiratory Medicine Unit, City Hospital, Edinburgh.
authors.forename: M F
authors.initials: MF
authors.lastname: Fitzpatrick
authors.forename: T
authors.initials: T
authors.lastname: Mackay
authors.forename: H
authors.initials: H
authors.lastname: Driver
authors.forename: N J
authors.initials: NJ
authors.lastname: Douglas
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D000068299:Salmeterol Xinafoate; D012893:Sleep Wake Disorders / Q000517:prevention & control; D013997:Time Factors
chemical_list: D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D000068299:Salmeterol Xinafoate; D000420:Albuterol